Literature DB >> 10947198

Proceedings of the 4th International Workshop of the Adrenoleukodystrophy International Research Group (ALD-IRG), University of York, 3 September 1998.

S Alger1, A Green, W Köhler, P Sokolowski, H Moser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947198     DOI: 10.1023/a:1005604012362

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  6 in total

1.  Lovastatin for X-linked adrenoleukodystrophy.

Authors:  I Singh; M Khan; L Key; S Pai
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

Review 2.  Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes.

Authors:  L Bezman; H W Moser
Journal:  Am J Med Genet       Date:  1998-04-13

3.  Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy.

Authors:  I Singh; K Pahan; M Khan
Journal:  FEBS Lett       Date:  1998-04-24       Impact factor: 4.124

Review 4.  Therapy of X-linked adrenoleukodystrophy: prognosis based upon age and MRI abnormality and plans for placebo-controlled trials.

Authors:  H W Moser; L Bezman; S E Lu; G V Raymond
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

5.  Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindreds.

Authors:  B M van Geel; J Assies; G J Weverling; P G Barth
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

6.  Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.

Authors:  S Kemp; H M Wei; J F Lu; L T Braiterman; M C McGuinness; A B Moser; P A Watkins; K D Smith
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

  6 in total
  1 in total

Review 1.  Rare diseases and the assessment of intervention: what sorts of clinical trials can we use?

Authors:  B Wilcken
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.